Feature | June 03, 2013

Medtronic CoreValve System Receives CE Mark for Transcatheter Valve-in-Valve Procedures

Replacing degenerated surgical valves with CoreValve results in hemodynamic improvements for patients

June 3, 2013 — Medtronic Inc. announced it has received CE mark for valve-in-valve (VIV) procedures using the CoreValve and CoreValve Evolut transcatheter aortic valve implantation (TAVI) systems in degenerated bioprosthetic surgical aortic valves. This is the first regulatory approval for VIV procedures, which provide a minimally invasive treatment option for patients whose surgical aortic valves have degenerated, and who are at extreme or high risk for surgery and would otherwise go untreated. The CoreValve VIV procedures are not approved in the United States.

Results from the largest global VIV registry, published in Circulation in November (“Transcatheter Aortic Valve Replacement for Degenerative Bioprosthetic Surgical Valves: Results from the Global Valve-in-Valve Registry”), showed the VIV approach resulted in considerable hemodynamic (blood flow) improvements, including a decrease in valve gradients (blood flow resistance). Positive procedural outcomes were maintained at one-year follow-up (with 89 percent survival at one year), which was comparable with other non-VIV TAVI studies.

“While surgical valves provide effective therapy for many patients, the replacement valves eventually degenerate over time, so VIV has become a topic of great clinical interest due to the needs of these patients,” said Ran Kornowski, M.D., chair of cardiology at Rabin Medical Center and Tel-Aviv University in Tel-Aviv, Israel, and senior author of the Global Valve-in-Valve registry. “European approval of the CoreValve procedure is a very important advance in the treatment of severe aortic stenosis and enables an entirely new group of patients to benefit from this transcatheter valve.”

The Global VIV registry evaluated the safety and efficacy of the VIV approach in 202 patients at 38 sites in Europe, North America, Australia, New Zealand and the Middle East, with 124 patients receiving the CoreValve system. In the study, the CoreValve system demonstrated superior hemodynamic outcomes and high procedural success rates (96.8 percent).

The valve-in-valve procedure, in which the CoreValve system is placed inside the degenerated surgical aortic valve through a low-profile, 18 French delivery catheter, is approved for use with all four CoreValve sizes (23 mm, 26 mm, 29 mm and 31 mm), as well as three delivery approaches (transfemoral, subclavian and direct aortic access).

“We are pleased to now extend this safe and less invasive, valve-in-valve procedure. This approach allows patients to avoid a second open-heart surgery to replace a failing surgical valve, which was originally performed to replace their own diseased valve.” said John Liddicoat, M.D., senior vice president of Medtronic, and president of the Medtronic Structural Heart Business. “Furthermore, the impressive improvements in hemodynamic performance, due to CoreValve’s supra-annular design, are showcased in the results of these valve-in-valve procedures.”

Each year approximately 200,000 people worldwide receive surgical aortic valves, which typically last 15 years or more. When the surgical valves degenerate due to the aging process, patients require another valve replacement. However, some patients are not eligible for a second open-heart surgery, and the transcatheter VIV procedure now may provide them with a new treatment option.

The Medtronic CoreValve system is available in the United States for investigational use only. In the Medtronic CoreValve U.S. Expanded Use Study, the U.S. Food and Drug Administration (FDA) has approved investigational VIV procedures in extreme-risk patients (part of the pivotal trial evaluating the CoreValve system in the United States).

For more information: www.medtronic.com

Related Content

Hitachi and West Virginia University Partner to Advance Left Ventricular Mechanical Function Evaluation
News | Cardiovascular Ultrasound| July 21, 2017
Hitachi Healthcare and the West Virginia University Heart and Vascular Institute announced the formation of a new...
First Patient Treated in U.S. Feasibility Study of LimFlow Critical Limb Ischemia Device
News | Peripheral Arterial Disease (PAD)| July 17, 2017
LimFlow SA announced enrollment of the first patient in the U.S. feasibility study of the LimFlow Percutaneous Deep...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Edwards Sapien 3 TAVR valve will be implanted in asymptomatic aortic stenosis patients in the EARLY TAVR Trial
Feature | Heart Valve Technology| July 14, 2017
July 14, 2017 — Morristown Medical Center, part of Atlantic Health System, has randomized the first patient in the wo
long-duration dual anti-platelet therapy (L-DAPT) compared to short-duration dual antiplatelet (S-DAPT) after DES stent implantation
News | Antiplatelet and Anticoagulation Therapies| July 12, 2017
June 12, 2017 — Researchers have evaluated the long-term efficacy and safety of long-duration dual anti-platelet ther
Ziosoft's PhyZiodynamics 4-D processing showing a replaced aortic valve

An example of Ziosoft's PhyZiodynamics 4-D processing showing a replaced aortic valve.

Technology | Computed Tomography (CT)| July 12, 2017
July 12, 2017 — At the 2017 annual meeting for the Society of Cardiovascular Computed Tomography (SCCT), Ziosoft show
Medtronic's CoreValve Evolut R gained FDA approval for intermediate risk patients

An illustration of the self-expanding CoreValve Evolut R TAVR valve half deployed in the aortic root.

Feature | Heart Valve Technology| July 10, 2017
The U.S. Food and Drug Administration (FDA) has cleared an additional indication to expand the use Medtronic's self-...
Patient Race, Gender Both Important in Predicting Heart Attack Symptoms in the ER
News | Cath Lab| July 07, 2017
Researchers at the George Washington University (GW) found that certain symptoms are more and less predictive of...
ACCESS PTS Study Demonstrates Efficacy of EKOS Therapy for Post-Thrombotic Syndrome
News | Deep Vein Thrombosis| July 07, 2017
BTG plc recently highlighted the results of the ACCESS PTS trial, presented at the Society for Vascular Medicine 28th...
Heartflow FFR-CT can noninvasively assess the hemodynamic impact of coronary lesions to avoid the need for an invasive angiogram.

HeartFlow FFR-CT can noninvasively assess the hemodynamic impact of coronary lesions to avoid the need for an invasive angiogram.

Technology | CT Angiography (CTA)| July 06, 2017
July 6, 2017 — GE Healthcare and HeartFlow Inc.
Overlay Init